Novo Nordisk broke ground May 4 on a new 7,500 m2 manufacturing facility in Kalundborg, Denmark. The company is investing 1.5 billion Danish kroner in the facility, which will produce active pharmaceutical ingredients for NovoSeven®and future products for treating hemophilia.
The investment is estimated to create 100 new production and engineering jobs in Kalundborg, where Novo Nordisk currently employs more than 2,800 people, according to the company. The facility is expected to be approved and fully operational by 2020.
“The investment in Kalundborg underscores our long-term ambition to create and maintain jobs in Denmark,” says Henrik Wulff, executive vice president, Product Supply, Novo Nordisk. “This year alone, we expect Novo Nordisk will create about 250 new jobs in Kalundborg, and we are always on the lookout for capable and highly-skilled employees.”
Established in 1969, the Kalundborg production site is Novo Nordisk’s largest with a total area of 1,000,000 m2.